{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:21:50Z","timestamp":1784290910456,"version":"3.55.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"ioM\u00e9rieux Australia"},{"name":"Department of Infectious Diseases and Microbiology, Concord Hospital"},{"name":"School of Medical, Molecular and Forensic Sciences, Murdoch University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Benzylpenicillin with ceftriaxone is used for outpatient antimicrobial therapy of Enterococcus faecalis infective endocarditis (EFIE) due to poor stability of aminopenicillins. The aim was to correlate the impact of benzylpenicillin-ceftriaxone synergy on EFIE treated with benzylpenicillin-ceftriaxone, and investigate whether simpler phenotypic methods can predict synergy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical outcomes of a retrospective cohort of EFIE patients were correlated with treatment and synergy. Isolates were assessed for synergy using the checkerboard method, compared with double disc diffusion (DDD) and layered and crossed gradient diffusion strip (GDS) tests, with sensitivity and specificity of these methods calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-eight episodes of EFIE in 34 patients were included; the majority received benzylpenicillin-ceftriaxone alone (n\u200a=\u200a16) or in sequence (n\u200a=\u200a12; any benzylpenicillin-ceftriaxone n\u200a=\u200a28), and 10 received other regimens. There was no statistical difference between any benzylpenicillin-ceftriaxone versus other therapies on outcomes, nor between benzylpenicillin-ceftriaxone synergy and outcome. GDS was an unreliable predictor of checkerboard synergy; DDD was reasonable. Five isolates lacked benzylpenicillin-ceftriaxone synergy (one also lacking ampicillin-ceftriaxone synergy); these all had high-level ceftriaxone resistance [zone diameter 6\u2005mm, or broth microdilution (BMD) MIC &amp;gt;512\u2005mg\/L]. Most isolates from relapse cases developed reduced zone diameters to ceftriaxone. Two isolates lacking synergy had the same mutation near the ceftriaxone response regulator (CroR) binding site in the pbp4 promoter region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ceftriaxone susceptibility, either MIC &amp;lt;512\u2005mg\/L by BMD or disc zone diameter &amp;gt;6\u2005mm, is the best predictor of ampicillin-ceftriaxone and particularly benzylpenicillin-ceftriaxone synergy in E. faecalis. There was no clear relationship between the absence of benzylpenicillin-ceftriaxone synergy and outcome in this highly comorbid cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf377","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:10:44Z","timestamp":1760011844000},"page":"3357-3366","source":"Crossref","is-referenced-by-count":2,"title":["Dual \u03b2-lactam synergy in\n                    <i>Enterococcus faecalis<\/i>\n                    and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes"],"prefix":"10.1093","volume":"80","author":[{"given":"April","family":"Gregson","sequence":"first","affiliation":[{"name":"Concord Clinical School, Faculty of Medicine and Health, University of Sydney , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakeel","family":"Mowlaboccus","sequence":"additional","affiliation":[{"name":"School of Medical, Molecular and Forensic Sciences, Murdoch University , Murdoch, WA ,","place":["Australia"]},{"name":"Department of Microbiology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital , Murdoch, WA ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi Mamoottil","family":"Sudeep","sequence":"additional","affiliation":[{"name":"School of Medical, Molecular and Forensic Sciences, Murdoch University , Murdoch, WA ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Concord Microbiology, Concord Repatriation and General Hospital, NSW Health Pathology , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jignasa","family":"Purani","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Laboratory, Centre for Infectious Diseases and Microbiology, Institute for Clinical and Pathological Sciences, Westmead Hospital, NSW Health Pathology , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Martinez","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Sciences, University of Sydney , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Coombs","sequence":"additional","affiliation":[{"name":"School of Medical, Molecular and Forensic Sciences, Murdoch University , Murdoch, WA ,","place":["Australia"]},{"name":"Department of Microbiology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital , Murdoch, WA ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9457-8262","authenticated-orcid":false,"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Laboratory, Centre for Infectious Diseases and Microbiology, Institute for Clinical and Pathological Sciences, Westmead Hospital, NSW Health Pathology , Sydney, NSW ,","place":["Australia"]},{"name":"School of Medical Sciences, Faculty of Medicine and Sciences, University of Sydney , Sydney, NSW ,","place":["Australia"]},{"name":"Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5238-9260","authenticated-orcid":false,"given":"Genevieve","family":"McKew","sequence":"additional","affiliation":[{"name":"Concord Clinical School, Faculty of Medicine and Health, University of Sydney , Sydney, NSW ,","place":["Australia"]},{"name":"Concord Microbiology, Concord Repatriation and General Hospital, NSW Health Pathology , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2025120206221914900_dkaf377-B1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/antibiotics9100657","article-title":"Enterococcus faecalis endocarditis and outpatient treatment: a systematic review of current alternatives","volume":"9","author":"Herrera-Hidalgo","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2025120206221914900_dkaf377-B2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/cid\/ciy064","article-title":"A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis","volume":"67","author":"Beganovic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025120206221914900_dkaf377-B3","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/cid\/ciae379","article-title":"Revisiting the evidence base that informs the use of adjunctive therapy for Enterococcus faecalis endocarditis: a systematic review and meta-analysis","volume":"79","author":"Prosty","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025120206221914900_dkaf377-B4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/cid\/cit052","article-title":"Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis","volume":"56","author":"Fern\u00e1ndez-Hidalgo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025120206221914900_dkaf377-B5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.7326\/0003-4819-146-8-200704170-00008","article-title":"Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone","volume":"146","author":"Gavald\u00e0","year":"2007","journal-title":"Ann Intern Med"},{"key":"2025120206221914900_dkaf377-B6","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2025120206221914900_dkaf377-B7","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC guidelines for the management of endocarditis","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur Heart J"},{"key":"2025120206221914900_dkaf377-B8","doi-asserted-by":"publisher","first-page":"e2326366","DOI":"10.1001\/jamanetworkopen.2023.26366","article-title":"Guidelines for diagnosis and management of infective endocarditis in adults: a WikiGuidelines group consensus statement","volume":"6","author":"McDonald","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025120206221914900_dkaf377-B9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/jcpt.12635","article-title":"Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis","volume":"43","author":"Gil-Navarro","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"2025120206221914900_dkaf377-B10","first-page":"338","article-title":"Stability of ampicillin in normal saline and buffered normal saline","volume":"20","author":"Maher","year":"2016","journal-title":"Int J Pharm Compd"},{"key":"2025120206221914900_dkaf377-B11","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/cid\/ciz594","article-title":"Penicillin as a potential agent for dual \u03b2-lactam therapy for enterococcal endocarditis","volume":"70","author":"Tritle","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025120206221914900_dkaf377-B12","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1093\/jac\/dkab132","article-title":"Outpatient continuous-infusion benzylpenicillin combined with either gentamicin or ceftriaxone for enterococcal endocarditis","volume":"76","author":"Briggs","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025120206221914900_dkaf377-B13","doi-asserted-by":"publisher","first-page":"dlab128","DOI":"10.1093\/jacamr\/dlab128","article-title":"A clinical and in vitro assessment of outpatient parenteral benzylpenicillin and ceftriaxone combination therapy for enterococcal endovascular infections","volume":"3","author":"Ingram","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2025120206221914900_dkaf377-B14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/23744235.2019.1672888","article-title":"Treatment of Enterococcus faecalis infective endocarditis with penicillin G plus ceftriaxone","volume":"52","author":"Suzuki","year":"2020","journal-title":"Infect Dis (Lond)"},{"key":"2025120206221914900_dkaf377-B15","doi-asserted-by":"publisher","first-page":"dlae168","DOI":"10.1093\/jacamr\/dlae168","article-title":"Outpatient parenteral antimicrobial therapy for patients with Enterococcus faecalis endocarditis using continuous infusion IV benzylpenicillin plus IV ceftriaxone","volume":"6","author":"Briggs","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2025120206221914900_dkaf377-B16","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1128\/AAC.39.9.1984","article-title":"Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis","volume":"39","author":"Mainardi","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206221914900_dkaf377-B17","doi-asserted-by":"publisher","first-page":"e0087122","DOI":"10.1128\/aac.00871-22","article-title":"Penicillin-binding proteins and alternative dual-beta-lactam combinations for serious Enterococcus faecalis infections with elevated penicillin MICs","volume":"67","author":"Cusumano","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206221914900_dkaf377-B18","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/microorganisms9102150","article-title":"In vitro synergism of penicillin and ceftriaxone against Enterococcus faecalis","volume":"9","author":"Thieme","year":"2021","journal-title":"Microorganisms"},{"key":"2025120206221914900_dkaf377-B19","doi-asserted-by":"publisher","first-page":"e0062122","DOI":"10.1128\/spectrum.00621-22","article-title":"Penicillin plus ceftriaxone versus ampicillin plus ceftriaxone synergistic potential against clinical Enterococcus faecalis blood isolates","volume":"10","author":"Cusumano","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2025120206221914900_dkaf377-B20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1128\/AAC.43.3.639","article-title":"Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides","volume":"43","author":"Gavald\u00e0","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206221914900_dkaf377-B21","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1093\/jac\/dkz173","article-title":"In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium","volume":"74","author":"Lorenzo","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025120206221914900_dkaf377-B22","doi-asserted-by":"publisher","first-page":"e01119-22","DOI":"10.1128\/mbio.01119-22","article-title":"CroR regulates expression of pbp4(5) to promote cephalosporin resistance in Enterococcus faecalis","volume":"13","author":"Timmler","year":"2022","journal-title":"mBio"},{"key":"2025120206221914900_dkaf377-B23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/jac\/dkae032","article-title":"Differential in vitro susceptibility to ampicillin\/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates","volume":"79","author":"Westbrook","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025120206221914900_dkaf377-B24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/cid\/ciad271","article-title":"The 2023 Duke-International Society for Cardiovascular Infectious Diseases criteria for infective endocarditis: updating the modified Duke criteria","volume":"77","author":"Fowler","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120206221914900_dkaf377-B25","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Thirty-Third Edition: M100","author":"CLSI","year":"2023"},{"key":"2025120206221914900_dkaf377-B26","volume-title":"Minimal Inhibitory Concentration Reading Guide\u2014Twelfth Edition: M07","author":"CLSI","year":"2024"},{"key":"2025120206221914900_dkaf377-B27","volume-title":"Disk Diffusion Reading Guide\u2014Fourteenth Edition: M02","author":"CLSI","year":"2024"},{"key":"2025120206221914900_dkaf377-B28","volume-title":"Antimicrobial Susceptibility Testing EUCAST Disk Diffusion Method\u2014Version 12.0","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2024"},{"key":"2025120206221914900_dkaf377-B29","volume-title":"Etest Application Guide","author":"bioM\u00e9rieux","year":"2010"},{"key":"2025120206221914900_dkaf377-B30","volume-title":"Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 13.1","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2023"},{"key":"2025120206221914900_dkaf377-B31","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1128\/JCM.01121-14","article-title":"When does 2 plus 2 equal 5? A review of antimicrobial synergy testing","volume":"52","author":"Doern","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2025120206221914900_dkaf377-B32","doi-asserted-by":"publisher","first-page":"e00361-18","DOI":"10.1128\/mBio.00361-18","article-title":"Structural and regulatory changes in PBP4 trigger decreased \u03b2-lactam susceptibility in Enterococcus faecalis","volume":"9","author":"Rice","year":"2018","journal-title":"mBio"},{"key":"2025120206221914900_dkaf377-B33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/cid\/ciac777","article-title":"Impact of Enterococcus faecalis endocarditis treatment on risk of relapse","volume":"76","author":"Danneels","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120206221914900_dkaf377-B34","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/jac\/dky051","article-title":"In vitro synergism and anti-biofilm activity of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis","volume":"73","author":"Thieme","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025120206221914900_dkaf377-B35","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1128\/JB.00995-15","article-title":"Functional dissection of the CroRS two-component system required for resistance to cell wall stressors in Enterococcus faecalis","volume":"198","author":"Kellogg","year":"2016","journal-title":"J Bacteriol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3357\/64739757\/dkaf377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3357\/64739757\/dkaf377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:25Z","timestamp":1764674545000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3357\/8292773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf377","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,17]]}}}